Immatics (NASDAQ:IMTX) Now Covered by Analysts at Deutsche Bank Aktiengesellschaft

Equities researchers at Deutsche Bank Aktiengesellschaft started coverage on shares of Immatics (NASDAQ:IMTX - Get Free Report) in a report issued on Wednesday, MarketBeat reports. The firm set a "buy" rating and a $10.00 price target on the stock. Deutsche Bank Aktiengesellschaft's price objective would indicate a potential upside of 83.82% from the stock's previous close.

Several other equities analysts have also recently weighed in on IMTX. Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a research note on Tuesday, April 1st. Wall Street Zen cut shares of Immatics from a "hold" rating to a "strong sell" rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $14.67.

Immatics Price Performance

NASDAQ IMTX traded up $0.30 during trading hours on Wednesday, reaching $5.44. 446,357 shares of the company's stock traded hands, compared to its average volume of 648,285. Immatics has a 52-week low of $3.30 and a 52-week high of $13.77. The firm has a 50-day simple moving average of $4.52 and a 200 day simple moving average of $5.62. The firm has a market cap of $661.23 million, a PE ratio of -8.24 and a beta of 0.87.

Immatics (NASDAQ:IMTX - Get Free Report) last released its quarterly earnings data on Tuesday, May 13th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04. The company had revenue of $20.12 million during the quarter, compared to the consensus estimate of $14.92 million. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. Sell-side analysts forecast that Immatics will post -0.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Vestal Point Capital LP raised its stake in Immatics by 14.6% during the 1st quarter. Vestal Point Capital LP now owns 7,192,700 shares of the company's stock worth $32,439,000 after acquiring an additional 917,700 shares during the period. Trexquant Investment LP purchased a new stake in shares of Immatics in the first quarter worth $783,000. Pale Fire Capital SE raised its position in shares of Immatics by 8.9% during the 1st quarter. Pale Fire Capital SE now owns 34,270 shares of the company's stock valued at $155,000 after purchasing an additional 2,808 shares during the period. T. Rowe Price Investment Management Inc. raised its position in shares of Immatics by 38.4% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 14,677,003 shares of the company's stock valued at $66,194,000 after purchasing an additional 4,072,226 shares during the period. Finally, Algert Global LLC lifted its stake in shares of Immatics by 20.6% during the 1st quarter. Algert Global LLC now owns 70,668 shares of the company's stock valued at $319,000 after buying an additional 12,072 shares in the last quarter. 64.41% of the stock is owned by hedge funds and other institutional investors.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.